Skip to content

In the BioHarmony Drug Report Database


Oxlumo (lumasiran) is an oligonucleotide pharmaceutical. Lumasiran was first approved as Oxlumo on 2020-11-19. It has been approved in Europe to treat primary hyperoxaluria. Oxlumo's patents are valid until 2035-10-09 (FDA).
Trade Name Oxlumo
Common Name Lumasiran
Indication primary hyperoxaluria
Drug Class
Get full access now